D
Celldex Therapeutics, Inc. CLDX
$25.92 -$0.93-3.46% NASDAQ
Recommendation
Prev Close
$25.92
Volume
361,236
Avg Vol (90D)
852,635
Market Cap
$1.72B
Dividend & Yield
--
52-Week Range
$14.40 - $30.50
P/E (TTM)
--
EPS (TTM)
-$3.38
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
A Look At Celldex Therapeutics (CLDX) Valuation After Recent Share Price Weakness
1/24/2026 - Simply Wall St
Celldex Therapeutics (CLDX, $26.85) price moved above its 50-day Moving Average on January 22, 2026
1/23/2026 - Tickeron - Technical Analysis
Celldex Expands Into Asthma: Early CDX-622 Trial Signals New Growth Angle for CLDX
1/21/2026 - TipRanks Financial Blog
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Sees Large Growth in Short Interest
1/19/2026 - MarketBeat
Celldex Therapeutics (CLDX, $25.67) Moving Average Convergence Divergence (MACD) Histogram turned negative on January 12, 2026
1/13/2026 - Tickeron - Stocks
Celldex Therapeutics (NASDAQ:CLDX) Trading Down 7.5% - Here's Why
1/13/2026 - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Trading Down 7.5% - Here's What Happened
1/13/2026 - Ticker Report
Celldex Therapeutics SVPs Engage In Heavy Transactions
1/12/2026 - Nasdaq News: Markets
Celldex Therapeutics SVPs Engage In Heavy Transactions
1/12/2026 - Yahoo! Finance: News
Celldex Therapeutics SVPs Engage In Heavy Transactions
1/12/2026 - Fool.com Headlines
How Advancing Antibody Pipeline And 2027 Cash Runway At Celldex Therapeutics (CLDX) Has Changed Its Investment Story
1/11/2026 - Simply Wall St
Celldex Therapeutics (CLDX, $27.38) Stochastic Oscillator left the overbought zone on January 09, 2026
1/10/2026 - Tickeron - Stocks
Reassessing Celldex Therapeutics (CLDX) Valuation As Shares Trade At A Discount To DCF Estimates
1/10/2026 - Simply Wall St
Celldex Therapeutics (CLDX, $27.35) Moving Average Convergence Divergence (MACD) Histogram turned positive on January 8, 2026
1/9/2026 - Tickeron - Technical Analysis
Is Celldex Therapeutics (CLDX) Pricing Reflect Its DCF Upside After Recent Share Swings
1/8/2026 - Simply Wall St
Celldex Advances Barzolvolimab Into Phase 3 for Chronic Inducible Urticaria: What Investors Should Watch
1/7/2026 - TipRanks Financial Blog
Celldex Therapeutics (CLDX, $26.28) price moved above its 50-day Moving Average on January 06, 2026
1/7/2026 - Tickeron - Technical Analysis
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of "Moderate Buy" by Analysts
1/7/2026 - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Trading 4.1% Higher - Should You Buy?
12/31/2025 - MarketBeat
Celldex Therapeutics (CLDX, $26.43) price moved above its 50-day Moving Average on December 30, 2025
12/31/2025 - Tickeron - Stocks
Simplify Asset Management Inc. Invests $2.20 Million in Celldex Therapeutics, Inc. $CLDX
12/30/2025 - MarketBeat
Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Declines By 20.9%
12/30/2025 - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What Happened
12/30/2025 - MarketBeat
Celldex Therapeutics (CLDX, $27.27) price moved above its 50-day Moving Average on December 22, 2025
12/23/2025 - Tickeron - Stocks
First Week of CLDX August 2026 Options Trading
12/22/2025 - Stock Options Channel
Income Statement
Total Revenue (TTM)
$2.60M
EBITDA (TTM)
-$252.86M
EBIT (TTM)
-$256.24M
Net Income (TTM)
-$224.53M
Balance Sheet
Total Assets (Q)
$648.44M
Total Debt (Q)
$2.62M
Total Liabilities (Q)
$50.08M
Book Value Per Share (Q)
$9.01
Cash Flow
Cash from Operations (TTM)
-$179.48M
Cash from Investing (TTM)
$177.69M
Cash from Financing (TTM)
$1.43M
Net Change in Cash (TTM)
-$362.00K
Filings
Filing Date
Monday, November 10, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
0.95
7-Day Total Return
-1.59%
30-Day Total Return
-8.05%
60-Day Total Return
-4.21%
90-Day Total Return
5.45%
Year to Date Total Return
-4.04%
1-Year Total Return
7.91%
2-Year Total Return
-30.94%
3-Year Total Return
-44.28%
5-Year Total Return
37.73%
52-week Low
Apr 09, 2025 - $14.40
52-week High
Dec 08, 2025 - $30.50
Valuation
Market Cap
$1.72B - Small Cap
Enterprise Value
$1.14B
Price/Sales (TTM)
662.92
Price/Book (Q)
2.88
Dividends and Shares
Shares Outstanding
66.42M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.celldex.com
Phone Number
908 200 7500
Address
Perryville III Building
Suite 220 - 53 Frontage Road
Hampton, NJ 08827
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The... more
NASDAQ 01/23/2026 4:00PM Eastern Quotes delayed